Hard to believe it has been a month since FMI stockholders woke up to the tremendous deal news with Roche. Hopefully it won't jinx the ongoing tender/vote process but I have been meaning to post some highlights of the coverage.
Genentech Redux? Roche Buys Majority Stake in Foundation Medicine
Ben Fidler (Xconomy)
Roche Spends $1.03 Billion For Majority Stake In Foundation Medicine
Matthew Herper (Forbes)
It Had to be You: Why Roche Was The Lone Suitor For Foundation
Steve Dickman (Xconomy)
I am also overdue for an FMI journal watch collection. So overdue in fact I will just take you to a PubMed link highlighting the recent articles about the application of FoundationOne.